Physician profile
Carter Hanson
NPI 1477209583
$2,859.94
in general payments reported to CMS, 2019-2025
28 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $513 · 2023: $1,329 · 2024: $541 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.68 | 2022-2024 | |
| Glaxosmithkline, LLC. | $294.75 | 2022-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Regeneron Healthcare Solutions, INC. | $271.04 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $222.71 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $215.56 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $208.77 | 2022-2024 | Rexulti |
| Genzyme Corporation | $179.65 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $136.81 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.34 | 2022-2023 | Xifaxan |
| Pfizer INC. | $97.35 | 2023-2024 | |
| Gilead Sciences, INC. | $96.88 | 2023-2024 | |
| Exact Sciences Corporation | $77.70 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $73.95 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $66.62 | 2022-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $65.78 | 2022-2023 | Trintellix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $61.32 | 2023-2024 | Farxiga, Airsupra |
| Aerin Medical INC. | $57.91 | 2024-2025 | |
| Integra Lifesciences Corporation | $41.61 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Inspire Medical Systems, INC. | $37.36 | 2025 | Inspire |
| Astellas Pharma US INC | $35.83 | 2023 | Veozah, Myrbetriq |
| Hikma Pharmaceuticals USA | $31.34 | 2024 | Ryaltris |
| Corcept Therapeutics | $24.72 | 2023 | Korlym |
| Nevro Corp. | $23.92 | 2022 | |
| Kerecis Limited | $23.38 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.39 | 2022 | |
| Viiv Healthcare Company | $16.24 | 2023 | Apretude |
| Currax Pharmaceuticals LLC | $16.05 | 2022 | |
| Amgen INC. | $15.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carter Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.